SRSrilakshmi M. Raj

Srilakshmi M. Raj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Srilakshmi M. Raj has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Mariko Isshiki

    Department of Genetics, Albert Einstein College of Medicine, New York, USA

    3 shared publications
  • John M. Greally

    Department of Genetics, Albert Einstein College of Medicine, Bronx, USA

    2 shared publications
  • Michael D. Cabana

    Affiliation Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, United States of America

    2 shared publications
  • Mirtha Colón

    Affiliation Hondurans Against AIDS/Casa Yurumein, Bronx, New York, United States of America

    2 shared publications
  • Paulette Spencer

    Affiliation Bronx Community Health Network, Bronx, New York, United States of America

    2 shared publications
  • Susan D. Klugman

    Affiliation Obstetrics & Gynecology and Women’s Health, Albert Einstein College of Medicine, Bronx, New York, United States of America

    2 shared publications

Latest Publications

  • Identifying the Genetic Ancestry of the Pediatric Obesity‐Related Asthma Variant (rs6494395) at Rps27l

    by David Yang, Anthony Griffen, Mariko Isshiki, John M. Greally, Deepa Rastogi, Srilakshmi M. Raj

    Background: Obesity‐related asthma (OA) is a severe asthma endotype that disproportionately affects children from minority ethnic groups. We previously identified downregulation of RPS27L (40S ribosomal protein S27‐like) in CD4+ (T‐helper) cells from children with OA compared to cells from healthy‐weight asthma that was associated with the C allele at the rs6494395 locus. Consistent with elevated allele frequencies in populations with Latino and African ancestries, we found a higher allele frequency of rs6494395 in Hispanic/Latino and African American children with OA. Aims: We tested the hypothesis that rs6494395 alleles have ancestry‐specific origins. Materials and Methods: We performed global genomic ancestry analysis using the program ADMIXTURE to characterize the proportions of continental genetic ancestry in each individual. Subsequently, we performed local genomic ancestry analysis using the program RFMix, to identify the ancestry of the genomic region containing the variant rs6494395 in the same multi‐ethnic pediatric cohort where the effect of the variant on obese‐related asthma was discovered. Results: Our results indicate that rs6494395 has an African genetic ancestral origin. Conclusions: Understanding the genetic underpinnings of pediatric OA in diverse populations can improve precision medicine approaches and address health disparities in asthma outcomes.


  • Open Access

    Genetic disease risks of under-represented founder populations in New York City

    by Mariko Isshiki, Anthony J. Griffen, Paul Meissner, Paulette Spencer, Michael D. Cabana, Susan D. Klugman, Mirtha Colón, Zoya Maksumova, Shakira Suglia, Carmen R. Isasi, et al.

    The detection of founder pathogenic variants, those observed in high frequency only in a group of individuals with increased inter-relatedness, can help improve delivery of health care for that community. We identified 16 groups with shared ancestry, based on genomic segments that are shared through identity by descent (IBD), in New York City using the genomic data of 25,366 residents from the All Of Us Research Program and the Mount Sinai BioMe biobank. From these groups we defined 7 as founder populations, mostly communities currently under-represented in medical genomics research, such as Puerto Rican and Garifuna. The enrichment analysis of ClinVar pathogenic or likely pathogenic (P/LP) variants in each group identified 201 of these damaging variants across the seven founder populations. We confirmed disease-causing variants previously reported to occur at increased frequencies in Ashkenazi Jewish and Puerto Rican genetic ancestry groups, but most of the damaging variants identified have not been previously associated with any such founder populations, and most of these founder populations have not been described to have increased prevalence of the associated rare disease. Twenty-two of 47 variants meeting Tier 2 prenatal screening criteria (1/100 carrier frequency within these founder groups) have never previously been reported. We show how population structure studies can provide insights into rare diseases disproportionately affecting under-represented founder populations, delivering a health care benefit but also a potential source of stigmatization of these communities, who should be part of the decision-making about implementation into health care delivery.


  • Open Access

    Genetic disease risks of under-represented founder populations in New York City

    by Mariko Isshiki, Anthony Griffen, Paul Meissner, Paulette Spencer, Michael D. Cabana, Susan D. Klugman, Mirtha Colón, Zoya Maksumova, Shakira Suglia, Carmen Isasi, et al.

    The detection of founder pathogenic variants, those observed in high frequency only in a group of individuals with increased inter-relatedness, can help improve delivery of health care for that community. We identified 16 groups with shared ancestry, based on genomic segments that are shared through identity by descent (IBD), in New York City using the genomic data of 25,366 residents from the All Of Us Research Program and the Mount Sinai Bio Me biobank. From these groups we defined 8 as founder populations, mostly communities currently under-represented in medical genomics research, such as Puerto Rican, Garifuna and Filipino/Pacific Islanders. The enrichment analysis of ClinVar pathogenic or likely pathogenic (P/LP) variants in each group identified 202 of these damaging variants across the 8 founder populations. We confirmed disease-causing variants previously reported to occur at increased frequencies in Ashkenazi Jewish and Puerto Rican genetic ancestry groups, but most of the damaging variants identified have not been previously associated with any such founder populations, and most of these founder populations have not been described to have increased prevalence of the associated rare disease. Twenty-five of 51 variants meeting Tier 2 clinical screening criteria (1/100 carrier frequency within these founder groups) have never previously been reported. We show how population structure studies can provide insights into rare diseases disproportionately affecting under-represented founder populations, delivering a health care benefit but also a potential source of stigmatization of these communities, who should be part of the decision-making about implementation into health care delivery. Author Summary: It is well recognized that genomic studies have been biased towards individuals of European ancestry, and that obtaining medical insights for populations under-represented in medical genomics is crucial to achieve health equity. Here, we use genomic information to identify networks of individuals in New York City who are distinctively related to each other, allowing us to define populations with common genetic ancestry based on genetic similarities rather than by self-reported race or ethnicity. In our study of >25,000 New Yorkers, we identified eight highly-interrelated founder populations, with 202 likely disease-causing variants with increased frequencies in specific founder populations. Many of these population-specific variants are new discoveries, despite their high frequency in founder populations. Studying recent genetic ancestry can help reveal population-specific disease insights that can help with early diagnosis, carrier screening, and opportunities for targeted therapies that all help to reduce health disparities in genomic medicine.